© 2018 American Heart Association, Inc. Cardiovascular regenerative medicine (CRM) has been defined as an innovative research field that includes all diagnostic and therapeutic strategies aimed at restoring cardiovascular health by enhancing the innate regenerative response of cardiac and vascular tissues.1 The TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) was created in 2015 with the vision of advancing CRM through synergy of basic discoveries and translational clinical efforts in the fight against cardiovascular failure and has grown to include >100 research groups worldwide.2 This unprecedented initiative stated as specific missions the redefinition of CRM and advanced therapy regenerative products, the establishment of discovery and development priorities for the next decade, and the attainment and dissemination of a consensual strategy to reinforce the field increasing its credibility. The first milestone of TACTICS has been achieved with the publication of a Global Consensus Document.1 However, given the amplitude and relevance of its different chapters, a more detailed description of all of them has been deemed necessary, following the same scheme of the Global Consensus Document and, therefore, discussing the main topics and priorities of the CRM field. This is the final aim of this Cardiovascular Regenerative and Reparative Medicine Circulation Research review series. In this first chapter, the following ones are presented and summarized in the form of and index of consecutive articles, which will cover biological fundamentals, preclinical models, and all clinical research-related issues. These articles will be regularly and subsequently published in this journal, on behalf of the TACTICS Consortium (Figure).